Compare · NGNE vs NVO
NGNE vs NVO
Side-by-side comparison of Neurogene Inc. (NGNE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NGNE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $213.34B, about 313.8x NGNE ($679.9M).
- Over the past year, NGNE is up 50.0% and NVO is down 30.9% - NGNE leads by 80.8 points.
- NGNE has been more active in the news (10 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 7 for NGNE).
- Company
- Neurogene Inc.
- Novo Nordisk A/S
- Price
- $34.22-3.14%
- $48.92+1.51%
- Market cap
- $679.9M
- $213.34B
- 1M return
- +13.39%
- +3.16%
- 1Y return
- +49.96%
- -30.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 10
- 5
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NGNE
- President and CFO Cvijic Christine Mikail sold $173,375 worth of shares (4,800 units at $36.12) as part of a pre-agreed trading plan (SEC Form 4)
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- President and CFO Cvijic Christine Mikail sold $166,586 worth of shares (4,800 units at $34.71) as part of a pre-agreed trading plan (SEC Form 4)
- Neurogene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Neurogene Inc.
- Neurogene Inc. Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by Neurogene Inc.
- Neurogene Inc. Announces Proposed Public Offering
- Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S